Piper Jaffray Remains Bullish on Horizon Pharma (HZNP) Following 'Strong' Q2, PT Trimmed to $33
Tweet Send to a Friend
Piper Jaffray analyst David Amsellem reiterated an Overweight rating on Horizon Pharma (NASDAQ: HZNP) but trimmed his price target to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE